Urogenital aging: solutions in clinical practice.
Urogenital aging, the most prevalent consequence of the menopause, affects at least 50% of postmenopausal women. It can lead to a lower quality of life, sexual problems, pain at intercourse/micturition and incontinence, but is yet an undertreated condition. The ideal treatment should relieve the vaginal symptoms of estrogen deficiency, have a localized effect, be convenient and easy to apply, safe to the endometrium and be without the unpleasant discharge produced by vaginal creams and pessaries. Vagifem, a new vaginal tablet containing 25 microg 17beta-estradiol, may fulfill many of the criteria required of an agent for the effective and efficient management of urogenital atrophy.
Notelovitz
M
M
Women's Medical and Diagnostic Center, Gainesville, Florida, USA.
D000282:Administration, Intravaginal; D000368:Aged; D000375:Aging / Q000187:drug effects / Q000502:physiology*; D001284:Atrophy / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects / Q000502:physiology*; D011379:Prognosis; D014566:Urogenital System / Q000187:drug effects / Q000502:physiology*; D014621:Vagina / Q000187:drug effects / Q000473:pathology
D004967:Estrogens